CM310 for uncontrolled seasonal allergic rhinitis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 interventional trial testing CM310, a monoclonal antibody that targets the interleukin‑4 receptor, in patients with uncontrolled seasonal allergic rhinitis. Participants will receive CM310 or a placebo and be followed for changes in nasal and ocular symptoms as well as safety measures. The trial is conducted at Beijing Tongren Hospital with voluntary informed consent and standard exclusion criteria to protect participant safety. Findings will help determine whether CM310 reduces symptom burden and improves quality of life compared with placebo.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Voluntarily sign the informed consent form.

Exclusion Criteria:

* Have any condition that are not suitable for participating in this study.

Where it's running

• Beijing Tongren Hospital, Capital Medical University
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Luo Zhang
• Email: dr.luozhang@139.com
• Phone: +86-13910830399

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rupatifen Fumarate Capsules for Seasonal Allergic Rhinitis

  This Phase 3 trial tests Rupatifen Fumarate Capsules in adults with seasonal allergic rhinitis to see if they reduce symptoms compared with Rupatadine Fumarate and placebo.

  Recruiting at 18 sites Phase 3 Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Baoding, Hebei and 17 other locations · NCT07711262

• TQH2722 injection plus regular allergy treatment for seasonal pollen allergy

  This trial will test whether adding TQH2722 injections to usual care helps adults (18–75) with seasonal allergic rhinitis who had poor symptom control during pollen season.

  Recruiting at 3 sites Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 29 other locations · NCT07398859

• Creating a risk assessment tool for thunderstorm asthma (CARISTA)

  This project will test whether lung tests, allergy blood markers and daily symptom tracking can predict which adults with hay fever in South‑Eastern Australia will have seasonal or thunderstorm-related asthma attacks over two spring seasons.

  Recruiting at 6 sites University of Melbourne · Albury, New South Wales and 5 other locations · NCT07055542

• Treatment of seasonal allergic rhinitis with MG-K10 monoclonal antibody injection

  This study is testing if an injection of a new medicine called MG-K10 can help people with seasonal allergies feel better compared to a placebo.

  Recruiting Phase 2/3 Shanghai Mabgeek Biotech.Co.Ltd · Beijing, Beijing Municipality · NCT06846385

• Acupuncture for treating seasonal allergies

  This study is testing whether acupuncture can help people with moderate-to-severe seasonal allergies feel better compared to a placebo treatment and standard medication.

  Recruiting Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing · NCT04815668

• Evaluating the Nasal Allergen Provocation Test for Allergen Immunotherapy

  This study is trying to see how well a nasal allergy test works for people starting treatment for allergic rhinitis and if it can help improve their care over time.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven, Vlaam Brabant and 1 other locations · NCT04544774

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.